Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica plc, a leading cell and gene therapy CDMO, has reported its total voting rights at 105,304,986 ordinary shares as of June 30, 2024, a key figure for shareholders to note for disclosure obligations. The company, recognized for its 25-year expertise in viral vectors, collaborates with major pharma and biotech firms, offering services from early-stage development to commercialization. Oxford Biomedica operates globally, with facilities in the UK, France, and the US.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
